The Technical Analyst
Revolution Medicines Inc [RVMD]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Revolution Medicines Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.94% $34.42
America/New_York / 19 apr 2024 @ 15:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 668.63 mill |
| EPS: | -3.86 |
| P/E: | -8.92 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 164.69 mill |
| Avg Daily Volume: | 1.448 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.92 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.52x |
| Company: PE -8.92 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.93 (-85.68%) $-29.49 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 33.18 - 35.80 ( +/- 3.81%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Goldsmith Mark A | Sell | 7 500 | Common Stock |
| 2024-04-10 | Goldsmith Mark A | Sell | 5 000 | Common Stock |
| 2024-04-10 | Goldsmith Mark A | Sell | 5 000 | Common Stock |
| 2024-04-10 | Patel Sushil | Sell | 2 155 | Stock Option (Right to Buy) |
| 2024-04-10 | Patel Sushil | Buy | 2 155 | Common Stock |
| INSIDER POWER |
|---|
| 73.06 |
| Last 99 transactions |
| Buy: 5 403 428 | Sell: 788 601 |
Forecast:
16:00 - $34.56
Live Trading Signals (every 1 min)
Forecast
1: 14:46 - $34.56
Forecast 2: 15:36 - $34.58
Forecast 3: 16:00 - $34.56
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $34.42 (-3.94% ) |
| Volume | 0.775 mill |
| Avg. Vol. | 1.448 mill |
| % of Avg. Vol | 53.50 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RVMD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $30.56 | N/A | Active |
|---|
RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Latest Press Releases
2024-04-09 15:34:00 - Press Release
Revolution Medicines Announces Publication On The Discovery Of And Translational Research For Rmc-6236, An Investigational Ras(on) Multi-selective Tri-complex Inhibitor Designed To Block Full Spectrum Of Oncogenic Ras(on) Proteins
Simultaneous publication and presentation of rmc-6236 chemical structure, preclinical data and case studies during the “kras: broadening the attack beyond g12c with small molecules and immuno-oncology" session at aacr 2024 in san diego simultaneous publication and presentation of rmc-6236 chemical structure, preclinical data and case studies during the “kras: broadening the attack beyond g12c with small molecules and immuno-oncology" session at aacr 2024 in san diego
2024-04-08 11:36:00 - Press Release
Revolution Medicines Announces Publications On The Discovery And Preclinical Profile Of Representative Of A New Class Of Ras(on) Multi-selective Inhibitors Designed To Block Full Spectrum Of Oncogenic Ras(on) Proteins
Two original papers in nature highlight the discovery and translational implications of rmc-7977, a ras(on) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in preclinical models of ras-mutant pancreatic ductal adenocarcinoma (pdac)
2024-04-04 16:05:00 - Press Release
Revolution Medicines To Participate In Upcoming Investor Conferences
Redwood city, calif., april 04, 2024 (globe newswire) -- revolution medicines, inc. (nasdaq: rvmd), a clinical-stage oncology company developing targeted therapies for patients with ras-addicted cancers, today announced that mark a. goldsmith, m.d., ph.d., the company's chief executive officer and chairman, will be a featured speaker at the 23rd annual needham healthcare conference and the stifel targeted oncology forum.
2024-03-28 16:05:00 - Press Release
Revolution Medicines To Deliver Multiple Presentations At The Upcoming American Association For Cancer Research Annual Meeting 2024
Redwood city, calif., march 28, 2024 (globe newswire) -- revolution medicines, inc. (nasdaq: rvmd), a clinical-stage oncology company developing targeted therapies for patients with ras-addicted cancers, today announced the company will deliver multiple presentations at the upcoming american association for cancer research (aacr) annual meeting 2024 being held april 5-10, 2024, in san diego, california.
2024-02-26 16:05:00 - Press Release
Revolution Medicines Reports Fourth Quarter And Full Year 2023 Financial Results And Update On Corporate Progress
Redwood city, calif., feb. 26, 2024 (globe newswire) -- revolution medicines, inc. (nasdaq: rvmd), a clinical-stage oncology company developing targeted therapies for patients with ras-addicted cancers, today announced its financial results for the quarter and full year ended december 31, 2023, and provided an update on corporate progress.
Latest News
2024-04-04 16:05:00 - GlobeNewsWire
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
2024-02-26 18:21:04 - Zacks Investment Research
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.63 per share a year ago.
2024-02-20 16:05:00 - GlobeNewsWire
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
2024-02-01 16:05:00 - GlobeNewsWire
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.
2024-01-17 11:11:59 - Zacks Investment Research
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
The mean of analysts' price targets for Revolution Medicines, Inc. (RVMD) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-12-15 17:04:19 - InvestorPlace
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
2023-11-16 17:35:36 - InvestorPlace
3 Biotech Stocks That Could Boom or Bust by 2025
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).
2023-11-06 20:04:08 - Seeking Alpha
Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO Steve Kelsey - President of Research & Development Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Ami Fadia - Needham Alec Stranahan - Bank of America Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2023 Earnings Conference Call.
2023-11-06 19:34:16 - Zacks Investment Research
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
Revolution Medicines, Inc. (RVMD) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.87 per share a year ago.
2023-10-31 16:15:00 - GlobeNewsWire
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.